They probably won’t need to do a phase 2 again as the results they achieved clearly show the advantages of this drug to the more seriously ill patients and it doesn’t matter that it has less effect on early stage patients, as sad as that is. Eventually as their illness progresses they will be given the drug to delay their kidney disease.
The results achieved are probably good enough for some sort of pharmacy deal.
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-208
-
- There are more pages in this discussion • 420 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
47.5¢ |
Change
-0.015(3.06%) |
Mkt cap ! $261.3M | |||
| Open | High | Low | Value | Volume |
| 49.5¢ | 49.5¢ | 46.5¢ | $2.742M | 5.746M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 158396 | 47.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.0¢ | 162500 | 2 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |